Total
USD $0.00
 
« Back to previous page

China Pharmaceutical Sector Report 2017 4th Quarter

An EMIS Insights Industry Report
EMIS is an ISI Emerging Markets Group Company
Date: February 2018
Pages: 60
Available in: English

In the third quarter of 2017, all subsectors of China’s pharmaceutical manufacturing sector, except the ready-prepared traditional Chinese medicines (TCMs), marked y/y growth in their revenues. The sizeable decline of 26.9% y/y in the TCM subsector’s revenue, however, had a negative impact on the whole sector’s revenue, which totalled RMB 726.2bn, down by 1.8% y/y. The sector’s total profit rose 15.9% to RMB 87.1bn, driven by the gradual implementation of the “two invoices” system. As a result of the ongoing environmental inspection campaign in Q3 2017 the production volume of pharmaceutical and medical products dropped by 1.5% y/y to 801,000 tonnes. The closure of a number of heavy-polluting producers of active pharmaceutical ingredients (APIs) caused a significant increase in API product prices. In Q3 2017 both the imports and the exports of pharmaceutical products marked y/y increases in value and volume terms. In this period the imports of pharmaceutical and medical products rose by 9.2% y/y to USD 6.5bn, while the exports increased by 9.1% y/y to USD 3.7bn. The number of pharmaceutical enterprises in China rose to 8,710 at the end of September 2017. Of these, 1,075 were loss making enterprises, compared to 1,119 at end-June and 1,373 at end-March 2017. The profitability of pharmaceutical manufacturers improved significantly after the implementation of the “two invoices” systems, which simplified drug supply chain and reduced distribution expenses.

 

This report provides a complete and detailed analysis of the transportation sector for China. EMIS Insights presents in-depth business intelligence in a standard format across countries and regions, providing a balanced mix between analysis and data.

What this report allows you to do:

  • Understand the key elements at play in the pharmaceutical sector in China
  • Access forecasts for growth in the sector
  • View key data on production and sales for the sector in China
  • Crystallise the forces both driving and restraining this sector in China
  • Build a complete perspective on sector trade, investment and employment
  • Understand the competitive landscape and who the major players are
  • View M&A activity and major deals
  • Gain an understanding of the regulatory environment for the sector in China
  • Build a clear picture of trends and issues for sub-sectors (western medicine, traditional Chinese medicine).

 

See below for a complete table of report contents:

China Pharmaceutical Sector Report 2017 4th Quarter - Page 1
USD 495.00 BUY FULL REPORT Payment methods include: DOWNLOAD A SAMPLE
Have a question about the report?

Email us at:
customerenquiries@emis.com

China Pharmaceutical Sector Report 2017 4th Quarter -  Page 3
China Pharmaceutical Sector Report 2017 4th Quarter -  Page 4
China Pharmaceutical Sector Report 2017 4th Quarter -  Page 13
China Pharmaceutical Sector Report 2017 4th Quarter -  Page 15
Once YOU HAVE COmPLETED YOUR PURCHASE,
YOU WILL BE ABLE TO DOWNLOAD THIS REPORT immediately as a pdf
If you have any questions, please contact customerenquires@emis.com